What is Keros Therapeutics Inc (KROS) stock price today?

Keros Therapeutics Inc (KROS) currently trades at $11.12 per share. The stock has a market capitalization of $228.75M and a P/E ratio of 5.03x.

Is KROS stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Keros Therapeutics Inc has a Smart Value Score of 54/100 (Grade C), resulting in a "Hold" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is the KROS stock price target for 2026?

WallStSmart's 12-month price target for Keros Therapeutics Inc is $11.09.

What is Keros Therapeutics Inc's revenue and earnings?

Keros Therapeutics Inc has trailing twelve-month (TTM) revenue of $244.06M with profit margins of 35.60%. Earnings per share (EPS) is $2.30.

KROS

Keros Therapeutics Inc

NASDAQ: KROS · HEALTHCARE · BIOTECHNOLOGY

$11.12

+0.18% today

Updated 2026-04-30

Market cap

$228.75M

P/E ratio

5.03

P/S ratio

0.94x

EPS (TTM)

$2.30

Dividend yield

—

52W range

$10 – $23

Volume

0.4M

Market cap

$228.75M

P/E ratio

5.03

P/S ratio

0.94x

EPS (TTM)

$2.30

Dividend yield

—

52W range

$10 – $23

Volume

0.4M

WallStSmart proprietary scores

out of 100

Grade: C

Hold

Investment rating

5.3

Growth

C+

5.0

Quality

C+

7.0

Profitability

B+

6.7

Valuation

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →201 stocks currently score above 75

Price targets

Analyst target

$22.57

+102.97%

12-Month target

$11.09

-0.27%

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy5 Buy4 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Profit margin 35.60% — above average

Risks

- Negative free cash flow $-27.43M

- Revenue declining -87.30% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$20.00M	$151000.00	$3.55M	$244.06M	$244.06M
Net income	$-104.68M	$-152.99M	$-187.35M	$87.01M	$-23.46M
EPS	—	—	—	—	$2.30
Free cash flow	$-71.30M	$-126.97M	$-162.80M	$105.95M	$-27.43M
Profit margin	-523.40%	-101,319.21%	-5,277.55%	35.65%	35.60%

Recent insider activity

Date	Insider	Type	Shares	Price
2026-04-15	BIENAIME, JEAN JACQUES	Buy	1,000	$11.70
2026-04-02	SEEHRA, JASBIR	Sale	55,000	—
2026-04-02	SEEHRA, JASBIR	Buy	55,000	$0.30

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
KROS	$228.75M	54	5.3	7.0	6.7	5.0	—	Buy
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Keros Therapeutics Inc trades at $11.12. representing a P/E of 5.03x trailing earnings. Our Smart Value Score of 54/100 indicates the stock is fair. TTM revenue stands at $244.06M. with profit margins at 35.60%.

Frequently asked questions

What is Keros Therapeutics Inc's stock price?

Keros Therapeutics Inc (KROS) trades at $11.12.

Is Keros Therapeutics Inc overvalued?

Smart Value Score 54/100 (Grade C, Hold).

What is the price target of Keros Therapeutics Inc (KROS)?

The analyst target price is $22.57, representing +103.0% upside from the current price of $11.12.

What is Keros Therapeutics Inc's revenue?

TTM revenue is $244.06M.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio0.94x

ROE19.90%

Beta0.99

50D MA$12.64

200D MA$15.65

Shares out0.02B

Float0.02B

Short ratio—

Avg volume0.4M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

KROS vs LLY →KROS vs JNJ →KROS vs ABBV →Stock screener →